Antimicrobial Resistance (AMR) is a complex challenge, requiring a comprehensive approach to address it. Our identified strategies centre around:

**RESEARCH AND SCIENCE**

**ANTIMICROBIAL STEWARDSHIP AND APPROPRIATE USE**

Initiatives to support access to a sufficient supply of quality-assured AMR-relevant products

Antimicrobial stewardship to ensure that existing antimicrobials are used appropriately

**AMR Industry Alliance contributions to tackling antimicrobial resistance:**

A spotlight on research and science, access and antimicrobial stewardship

**THE HIGHLIGHTS**

Alliance member contributions to tackling AMR (1 April 2021 and 31 March 2023)

- **Approximately USD 2 billion** was invested annually by 34 companies in 2021 and 2022 fiscal years.

**LOOKING TO THE FUTURE**

Investing in research and science to develop novel diagnostics, antimicrobials and vaccines

Strengthening collaboration with the private, public and not-for-profit sectors could support future Alliance activities to improve access to antimicrobials and enhance antimicrobial stewardship across diverse geographies.

Click here to read more about this work.

The AMR Industry Alliance is a coalition of 77 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and 10 trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance will ensure that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and will measure progress made in the fight against antimicrobial resistance.

amrindustryalliance.org